Russia’s Sputnik V gets Emergency Use authorisation nod in India
New Delhi: Russia’s Sputnik V got approval from the Subject expert committee (SEC) for Emergency Use Authorisation (EUA), making it the third Covid-19 vaccine to...
covid-19 vaccine
China mulls mixing vaccines to improve efficacy of jabs
Beijing: China is considering the mixing of different Covid-19 vaccines to improve the relatively low efficacy of its existing options, a top health expert has...
Pfizer seeks Covid vaccine authorization for 12-15 year olds in US
Washington: Pfizer-BioNTech asked for authorization Friday to use their Covid-19 vaccine on 12-15 year olds in the United States. The companies said in a statement...
Johnson & Johnson set to begin India trial of its single-shot vaccine, says report
Johnson & Johnson has told Indian regulators that it will soon begin clinical trials of its single-shot Covid-19 vaccine in the country. The U.S. drugs...
Panacea Biotec soars 17% after company signs deal to produce Sputnik V vaccine doses
Panacea Biotec shares surged on Tuesday after the company signed a deal with the Russian Direct Investment Fund (RDIF) to produce 100 million doses per...
RDIF ties up with Panacea for Covid-19 vaccine
Russia’s sovereign wealth fund, Russian Direct Investment Fund (RDIF) and domestic firm, Panacea Biotec announced a tie up to produce 100 million doses per year...
Johnson & Johnson testing vaccine on teens
Johnson & Johnson has started testing its Covid-19 vaccine on adolescents, beginning with those ages 16 and 17. The teens will be added to an...
China vaccine maker Sinovac says doubles production capacity
Beijing: Chinese biopharmaceutical firm Sinovac said Friday a third production line for its Covid-19 vaccine has been put into use, doubling its annual capacity of...
Covid-19: Centre’s expert panel allows clinical trials for third dose of Covaxin
The expert panel of India’s drug regulator, DCGI, has permitted Bharat Biotech to give a third dose of Covaxin to a few volunteers in its...
Pfizer Covid-19 shot 91% effective in updated data, protective against South African variant
– Pfizer Inc and BioNTech said on Thursday their Covid-19 vaccine is around 91% effective at preventing the disease, citing updated trial data that included...